Analysts have been eager to weigh in on the Healthcare sector with new ratings on Terns Pharmaceuticals (TERN – Research Report), Abbott Labs (ABT – Research Report) and Arcutis Biotherapeutics (ARQT – Research Report).
Terns Pharmaceuticals (TERN)
In a report issued on April 18, Graig Suvannavejh from Mizuho Securities reiterated a Buy rating on Terns Pharmaceuticals, with a price target of $10.00. The company’s shares closed last Friday at $4.56, close to its 52-week low of $3.26.
According to TipRanks.com, Suvannavejh is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Terns Pharmaceuticals with a $14.92 average price target, implying a 225.1% upside from current levels. In a report issued on April 3, Jefferies also assigned a Buy rating to the stock with a $22.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Abbott Labs (ABT)
In a report issued on April 18, Anthony Petrone from Mizuho Securities assigned a Hold rating to Abbott Labs, with a price target of $115.00. The company’s shares closed last Friday at $107.28.
According to TipRanks.com, Petrone is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Abbott Labs with a $127.07 average price target.
Arcutis Biotherapeutics (ARQT)
In a report issued on April 18, Uy Ear from Mizuho Securities reiterated a Buy rating on Arcutis Biotherapeutics, with a price target of $17.00. The company’s shares closed last Friday at $9.10.
According to TipRanks.com, Ear is a 3-star analyst with an average return of
Arcutis Biotherapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $16.40, implying a 75.2% upside from current levels. In a report issued on April 12, Needham also maintained a Buy rating on the stock with a $16.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on TERN:
- Terns Pharmaceuticals Appoints Melita Sun Jung as Chief Business Officer
- Terns Pharmaceuticals appoints Melita Sun Jung as chief business officer
- 3 Best Stocks to Buy Now, 4/4/2024, According to Top Analysts
- Terns Pharmaceuticals price target lowered to $18 from $19 at UBS
- Terns Pharmaceuticals price target lowered to $15 from $17 at JMP Securities
